Gong NanLing, Wei Heming, Chowdhury Sanaul Haq, Chatterjee Subroto
Johns Hopkins Singapore-National Heart Centre Vascular Biology Program, 41 Singapore Science Park II, Singapore 117610.
Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6490-5. doi: 10.1073/pnas.0308684101. Epub 2004 Apr 14.
Despite the importance of platelet/endothelial cell adhesion molecule-1 (PECAM-1, CD31) in the adhesion and diapedesis of monocytes/lymphocytes, little is known about the mechanisms by which it is regulated. We explored the role of a glycosphingolipid, lactosylceramide (LacCer), in modulating PECAM-1 expression and cell adhesion in human monocytes. We observed that LacCer specifically exerted a time-dependent increase in PECAM-1 expression in U-937 cells. Maximal increase in PECAM-1 protein occurred after incubation with LacCer for 60 min. LacCer activated PKCalpha and -epsilon by translocating them from cytosol to membrane. This was accompanied by the activation of phospholipase A(2) (PLA(2)) and the increase of cell adhesion, which were abrogated by chelerythrine chloride, 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)-maleimide and 12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)-carbazole (GO 6976) (PKC inhibitors). Similarly, bromoenol lactone (a Ca(2+)-independent PLA(2) inhibitor) and methyl arachidonyl fluorophosphonate (an inhibitor of cytosolic PLA(2) and Ca(2+)-independent PLA(2)) inhibited LacCer-induced PLA(2) activity. Bromophenacyl bromide (a PLA(2) inhibitor) abrogated LacCer-induced PECAM-1 expression, and this was bypassed by arachidonic acid. Furthermore, the arachidonate-induced up-regulation of PECAM-1 was abrogated by indomethacin [a cyclooxygenase (COX)-1 and -2 inhibitor] or N-[2-(cyclohexyloxy)-4-nitrophenyl]-methanesulfonamide (a COX-2 inhibitor) but not nordihydroguaiaretic acid (a lipoxygenase inhibitor). In sum, PKCalpha/epsilon are the primary targets for the activation of LacCer. Downstream activation of intracellular Ca(2+)-independent PLA(2) and/or cytosolic PLA(2) results in the production of arachidonic acid, which in turn serves as a precursor for prostaglandins that subsequently stimulate PECAM-1 expression and cell adhesion. These findings may be relevant in explaining the role of LacCer in the regulation of PECAM-1 and related pathophysiology.
尽管血小板/内皮细胞黏附分子1(PECAM-1,CD31)在单核细胞/淋巴细胞的黏附和渗出过程中具有重要作用,但其调控机制却鲜为人知。我们探究了一种糖鞘脂——乳糖神经酰胺(LacCer)在调节人单核细胞中PECAM-1表达及细胞黏附中的作用。我们观察到,LacCer能使U-937细胞中PECAM-1的表达随时间依赖性增加。与LacCer孵育60分钟后,PECAM-1蛋白的增加达到最大值。LacCer通过将蛋白激酶Cα(PKCα)和蛋白激酶Cε(PKCε)从胞质溶胶转运至细胞膜来激活它们。这伴随着磷脂酶A2(PLA2)的激活以及细胞黏附的增加,而氯化白屈菜红碱、2-[1-(3-二甲基氨基丙基)-1H-吲哚-3-基]-3-(1H-吲哚-3-基)-马来酰亚胺和12-(2-氰基乙基)-6,7,12,13-四氢-13-甲基-5-氧代-5H-吲哚并(2,3-a)吡咯并(3,4-c)-咔唑(GO 6976,PKC抑制剂)可消除这些作用。同样,溴代烯醇内酯(一种不依赖Ca2+的PLA2抑制剂)和甲基花生四烯酰氟磷酸酯(一种胞质型PLA2和不依赖Ca2+的PLA2的抑制剂)可抑制LacCer诱导的PLA2活性。溴苯甲酰溴(一种PLA2抑制剂)可消除LacCer诱导的PECAM-1表达,而花生四烯酸可绕过此抑制作用。此外,花生四烯酸诱导的PECAM-1上调被吲哚美辛[一种环氧化酶(COX)-1和-2抑制剂]或N-[2-(环己氧基)-4-硝基苯基]-甲磺酰胺(一种COX-2抑制剂)消除,但未被去甲二氢愈创木酸(一种脂氧合酶抑制剂)消除。总之,PKCα/ε是LacCer激活的主要靶点。细胞内不依赖Ca2+的PLA2和/或胞质型PLA2的下游激活导致花生四烯酸的产生,花生四烯酸进而作为前列腺素的前体,随后刺激PECAM-1表达和细胞黏附。这些发现可能有助于解释LacCer在PECAM-1调节及相关病理生理学中的作用。